3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
9
Head & Neck
2
Gastrointestinal
2
Dermatologic
2
Lymphoid
1
Gynecologic
1
CNS
1
Conditions
Uterine Cervical Neoplasms
1
Interventions
Paclitaxel
153
Carboplatin
123
Bevacizumab
87
Cisplatin
66
pembrolizumab
58
Taxes
51
Gemcitabine
51
liposomal doxorubicin
39
Topotecan
37
olaparib
31
Immunoglobulin G
27
Disulfides
26
Cyclophosphamide
24
Brachytherapy
22
Docetaxel
21
human papillomavirus vaccine, L1 type 16, 18
20
niraparib
19
Platinum
19
Nivolumab
18
Magnetic Resonance Spectroscopy
18
1,2-diaminocyclohexaneplatinum II citrate
18
rucaparib
17
durvalumab
16
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
16
Doxorubicin
16
Radiotherapy, Intensity-Modulated
14
Radiation
13
Albumin-Bound Paclitaxel
13
fludarabine phosphate
12
fludarabine
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Tiragolumab
×
Gynecologic
×
Clear all
NCT04300647
2026-03-12
SKYSCRAPER-04
Hoffmann-La Roche
Phase 2
Completed
172 enrolled
27 charts